Sinocelltech Group (China)

Recent papers from Sinocelltech Group (China)

1. Targeted delivery of boron depots containing immune adjuvant to achieve efficient cancer therapy via a combination of BNCT and cancer vaccineCancer Nanotechnology · 2026
2. Population Pharmacokinetic Modeling of Adalimumab Biosimilar SCT630 and Humira® in Healthy Participants and Patients with Moderate to Severe Plaque Psoriasis to Establish PK SimilarityCurrent Therapeutic Research · 2026
3. Anti-PD-1 monoclonal antibody suppresses hepatitis B virus in patients with hepatocellular carcinomaChinese Medical Journal · 2026
4. Baseline Anti-SARS-CoV-2 IgG and Protection from Symptomatic Infection: Post Hoc Analysis of the SCTV01E Phase 3 Randomized TrialVaccines · 2025
5. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialSignal Transduction and Targeted Therapy · 2025
6. Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.2025
7. Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination historyMicrobiology Spectrum · 2025
8. Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trialContemporary Clinical Trials Communications · 2025
9. Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trialTranslational Lung Cancer Research · 2025
10. Fc-Modified Antibody in Hospitalized Severe COVID-19 PatientsVaccines · 2025
11. Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal AntibodyPharmaceuticals · 2025
12. Developmental and reproductive toxicity (DART) study of a novel SARS-CoV-2 tetravalent recombinant protein vaccine (SCTV01E) in ratsReproductive Toxicology · 2025
13. Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variantsExpert Review of Vaccines · 2025
14. Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseasesRheumatology and Immunology Research · 2024
15. Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trialResearch and Practice in Thrombosis and Haemostasis · 2024
16. Digitally-assisted structure design of a large-size proton exchange membrane fuel cellEnergy & Environmental Science · 2024
17. Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in MiceVaccines · 2024
18. Immunogenicity and Safety of Omicron-Containing Multivalent COVID-19 Vaccines in Unvaccinated and Previously Vaccinated AdultsVaccines · 2024
19. Validation of a triple‐color pseudovirion‐based neutralization assay for immunogenicity assessment of a 14‐valent recombinant human papillomavirus vaccineJournal of Medical Virology · 2024
20. Current status and future directions for the development of human papillomavirus vaccinesFrontiers in Immunology · 2024